HIV/AIDS management: Trial shows importance of cotrimoxazole prophylaxis in malaria-endemic regions

By: | Tags: , , | Comments: 0 | January 5th, 2016

Cotrimoxazole (CTX) discontinuation is inferior to CTX continuation among ART-treated, immune-reconstituted HIV-infected adults living in a malaria-endemic region, according to results of a recent trial. These trial findings were important for December 2014 WHO guidelines recommending that CTX prophylaxis be continued regardless of CD4 cell count or HIV/AIDS clinical stage in settings where malaria is endemic and/or severe bacterial infections are common.


Thank you very much for your submission! We will get back to you as soon as possible!